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Abstract
Background: In many industrialized countries routine vaccination with the 23-valent pneumococcal polysaccharide
vaccine (PPSV-23) is recommended to prevent pneumococcal disease in the elderly. However, vaccine-induced
immunity wanes after a few years, and there are controversies around revaccination with PPSV-23. Here, we
systematically assessed the effectiveness and safety of PPSV-23 revaccination.
Method: We conducted a systematic literature review in MEDLINE, EMBASE, and Cochrane Central Register of
Controlled Trials from inception to June 2015. We included all study types that compared effectiveness,
immunogenicity and/or safety of PPSV-23 as a primary vs. a revaccination dose in persons aged 50 years and older.
With respect to immunogenicity, we calculated the ratio of geometric mean antibody concentrations and
opsonophagocytic indexes at identical time-points after primary and revaccination. Additionally, we compared rates
and severity of adverse events (AEs) after primary and revaccination.
Results: We included 14 observational studies. 10 studies had a prospective design and analysed data on (i) the
same individuals after a first and a second dose of PPSV-23 given 1 to 10 years later (n = 5) or (ii) two groups
consisting of participants receiving PPSV-23 who were either vaccine-naïve or had received a first PPSV-23 dose 3 to
13 years earlier (n = 5). Three studies used electronic data bases to compare AEs after primary vs. revaccination
doses of PPSV-23 after 1 to 10 years and one study had a cross-sectional design. Number of participants in the non-
register-based and register-based studies ranged from 29 to 1414 and 360 to 316,000, respectively. 11 out of 14
included studies were at high risk of bias, three studies had an unclear risk of bias. None of the studies reported
data on clinical effectiveness. Immunogenicity studies revealed that during the first two months antibody levels
tended to be lower after revaccination as compared to primary vaccination. Thereafter, no obvious differences in
antibody levels were observed. Compared to primary vaccination, revaccination was associated with an increased
risk of local and systemic AEs, which, however, were usually mild and self-limiting. The risk and severity of AEs
appeared to decrease with longer intervals between primary and revaccination.
Conclusion: Data comparing the effectiveness of primary vs. revaccination with PPSV-23 are still lacking, because
there are no studies with clinical endpoints. Data from observational studies indicates that revaccination with
PPSV-23 is likely to induce long-term antibody levels that are comparable to those after primary vaccination.
Given the high disease burden and the waning of vaccine-induced immunity, revaccination with PPSV-23 could
be considered in the elderly. The increased risk of local and systemic AEs can likely be mitigated when giving
revaccination at least five years after the primary dose. Adequately powered randomized controlled trials using
clinical endpoints are urgently needed.
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Background
Pneumococcal disease is a major cause of morbidity and
mortality in the elderly population worldwide [1–3].
Therefore, National Immunization Technical Advisory
Groups (NITAGs) in most industrialized countries
recommend vaccination of the elderly against pneumo-
coccal disease [4–6]. There are currently two different
pneumococcal vaccines approved for the use in the
elderly: a polysaccharide vaccine containing 23 different
capsular polysaccharides (serotypes) of Streptococcus
pneumoniae (PPSV-23) and a 13-valent conjugate
vaccine (PCV-13).
PPSV-23 has been available since 1983. There is
evidence that its protective effect declines already 3 to 5
years after vaccination [7, 8]. At the same time pneumo-
coccal disease incidence among the elderly increases
with age, which calls for PPSV-23 revaccination [9].
However, it has been postulated that repeat vaccination
leads to hypo-responsiveness resulting in diminished
antibody response [10]. Moreover, conflicting reports
exist regarding an increased risk of adverse events (AE)
following revaccination, as compared to the primary
vaccine dose [11–14].
After licensure of PCV-13 had been extended for
adults in 2011, many NITAGs continue to recommend
PPSV-23 for elderly [4, 5, 15, 16]. Due to significant herd
protection effects induced by routine childhood vaccin-
ation with PCV-13, those additional 11 serotypes in PPSV-
23, which are not covered by PCV-13, are gaining epi-
demiological importance also among the elderly [17–19].
Therefore, the questions related to PPSV-23 revaccination
continue to be of high relevance, both for clinicians but
also for many NITAGs that are in the process of updating
their guidelines on adult pneumococcal vaccination in view
of new evidence and the licensure of PCV-13 for adults.
The purpose of this review was therefore to systemat-
ically assess differences in the effectiveness, immunogen-
icity and safety of revaccination as compared to primary
vaccination with PPSV-23 in the elderly population.
Methods
PRISMA-guideline and study protocol
The systematic review was performed according to the
Preferred Reporting Items for Systematic Reviews and
Meta-analyses (PRISMA) statement [20] and was
prospectively registered with the international pro-
spective register of systematic reviews (PROSPERO)
(Reg. no. CRD42015024145).
Eligibility criteria
We evaluated all original studies that reported effective-
ness, immunogenicity or safety of revaccination with
PPSV-23 as compared to a primary PPSV-23 dose in
persons aged 50 years or older, irrespective of underlying
comorbidities. No restrictions were made regarding pub-
lication language and publication status (published/un-
published studies). We excluded studies in which other
vaccine types were used (e.g., experimental vaccines;
pneumococcal polysaccharide vaccines with less than 23
serotypes [e.g., PPSV-14]; pneumococcal conjugate
vaccines) or if a revaccination dose was administered
within 1 year of the first PPSV-23 dose.
Outcomes
Regarding vaccine effectiveness, we considered all clinical
outcomes including invasive pneumococcal disease, pneu-
monia (vaccine-type and all-types), as well as non-specific
outcomes such as all-cause mortality or hospitalization.
Immunogenicity data were considered, if geometric mean
antibody concentrations (GMCs) or opsonophagocytic
indexes (OPIs) were measured at the same interval after
primary vaccination and revaccination dose (e.g., 1 month
after primary and 1 month after revaccination), respect-
ively. Since seroconversion is difficult to define in the a-
bsence of a validated protective threshold, we evaluated
absolute antibody levels (GMC or OPA titers) rather than
seroconversion rates. Regarding safety, we considered all
types of local and systemic AE that were reported in the
included studies.
Literature search
Electronic databases searched were MEDLINE, EMBASE,
and Cochrane Central Register of Controlled Trials (date
of last search 26.06.2015). The search strategy included
both keywords and MESH terms related to effectiveness,
immunogenicity or safety of PPSV-23. For complete
search strategy, see Additional file 1. In addition, we
manually searched reference lists of all relevant original
studies and reviews and searched ClinicalTrials.gov for
additional studies.
Literature screening and data extraction
Two reviewers (CR, TH) independently screened titles,
abstracts and full text articles. From eligible studies, two
reviewers (CR and GF) extracted study data and assessed
methodological quality, using standardized extraction
forms. The extraction forms were pilot tested with the
first two identified studies. After calibration of the ex-
traction process, CR and GF finally extracted the follow-
ing information: author, publication year, country, study
design, study population, age of participants, study size,
number of PPSV-23 doses administered, time span be-
tween first and revaccination doses, outcome measures,
laboratory methods, serotypes measured, confounders
considered in the statistical analysis and potential con-
flicts of interests of the authors. In case of disagreements
regarding the screening process, data extraction, and
quality assessment a final decision was made by
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consensus or resolved by a third reviewer (GF [literature
screening] or TH [data extraction process]).
Risk of bias assessment
We used the Cochrane risk of bias tool to assess risk
of bias for RCTs [21] and the Critical Appraisal Skills
Program (CASP) tool for observational studies (http://
www.casp-uk.net/checklists). According to the suggestions
of the Cochrane Collaboration, we gave particular attention
to the domains risk of selection bias, detection bias and at-
trition bias in observational studies. For each study, risk of
bias appraisal was expressed as considered judgment as ei-
ther “low”, “high” or “unclear”.
Statistical analysis
Abstracted data were aggregated in tables. Risk ratios
(RR), odds ratios (OR) and corresponding 95% confi-
dence intervals (95% CIs) were either calculated or
directly extracted from the publications, if available. To
assess differences in serotype-specific GMCs after the
primary and revaccination dose, we graphically displayed
numbers with 95% CI for the most commonly analyzed
serotypes 4, 6B, 14 and 23 F. We also calculated GMC
(and OPI) ratios (i.e., GMC (OPI) after revaccination/
GMC (OPI) after primary vaccination) with correspond-
ing 95% CIs at each available time point. A ratio of > 1
indicates a higher antibody level after revaccination than
after primary vaccination. A ratio of < 1 indicates a
lower antibody level after revaccination than after
primary vaccination. Ratios with 95% CIs were calcu-
lated by back transforming the mean difference
GMCs between the vaccination groups on the loga-
rithmic scale [22].
Ratios are displayed separately for each study and for
the most commonly analyzed serotypes. Due to marked
differences within studies (immunogenicity differences
between serotypes) and between studies (e.g., different
study populations, different time spans from primary
vaccination to revaccination, different laboratory
methods), we did not perform meta-analyses. Calcula-
tions were performed using STATA 12 (StataCorp LP,
Texas, USA).
Results
The literature search yielded a total of 1162 titles and
two additional studies were identified through other
sources (Clinicaltrials.gov; reference list of an identified
review) (Fig. 1). Finally, 14 studies fulfilled the eligibility
criteria [11–13, 22–32]. For excluded studies see
Additional file 1.
Characteristics of included studies
Of the 14 studies, two studies were randomized
controlled trials (RCTs) [23, 31]. However, since only
data from one study arm were relevant for our research
question, we treated both trials as cohort studies. The
remaining studies were prospective (n = 8) or retrospect-
ive (n = 3) cohort studies, and one study had a cross-
sectional design (for study characteristics see Table 1).
The majority of studies comprised resident elderly popu-
lations (n = 10), the remaining included only patients
with chronic obstructive pulmonary disease [23, 29], pa-
tients with a history of community-acquired pneumonia
[24] or renal transplant recipients [31]. Five studies had
a longitudinal design in which the same individuals re-
ceived a primary dose and a revaccination with PPSV-23
one to ten years later [22, 24, 28, 29, 31].
In 6 studies two different study groups were compared:
one group consisted of participants who had received a
primary PPSV-23 dose, and the second group comprised
those who had received one [12, 13, 23, 25] or more than
one [26, 30] PPSV-23 revaccination doses after 3–13 years.
One study compared participants who had received at
least three PPSV-23 doses as compared to those who had
received a primary or second dose of PPSV-23 [32]; two
studies [11, 27] compared three study groups in which
participants had received a first, second or third dose of
PPSV-23 (after 1–22 years). In most included studies, par-
ticipants of the revaccination group were older and/or had
more underlying comorbidities as compared to partici-
pants who received a primary PPSV-23 dose (see Table 2).
Reported outcomes
None of the studies reported effectiveness of PPSV-23
against clinical outcomes. Three studies [23–25] reported
immunogenicity data, four studies [26, 27, 30, 32] reported
safety data and seven studies [11–13, 22, 28, 29, 31, 33]
reported both. Three publications reported data from
partially overlapping study populations [12, 25, 28]; how-
ever, data from non-overlapping subgroups were extracted
from all three papers. The time interval from primary to
revaccination varied widely within and between studies
with a range from 6 months to 22 years (Table 1).
Although in the study of Shih et al. [30] some participants
received the revaccination dose within one year, this study
was not excluded, since this subgroup of vaccinees repre-
sented less than 10% of the entire study population.
Risk of bias in individual studies
In 11 (78%) studies risk of bias was high [11–13, 22–24,
26, 28, 29, 31, 32]. This was mainly due to insufficient
control for confounders or due to a high risk of selection
bias during the recruitment process. In the remaining
three studies [25, 27, 30], risk of bias was unclear owing
to non-specific disease diagnosis codes (ICD-9 codes)
collected within a passive surveillance system or since
selection bias might have occurred during recruitment
of the study participants.
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Immunogenicity of primary vaccination and revaccination
with PPSV-23
Nine studies used enzyme-linked immunosorbent assays
(ELISAs) to measure serotype-specific anti-pneumococcal
immunoglobulin G (IgG) levels, but only three studies
[23, 29, 31] followed the current World Health
Organization (WHO)-approved ELISA protocol (Table 1).
Four studies [11, 23, 25, 29] additionally assessed func-
tional antibody activity assay (OPA). One study [22]
reported OPA results only. The number of analyzed sero-
types ranged from 3 to 13. One study [24] reported only
combined GMCs against six different serotypes and two
studies did not provide data on 95% CIs [23, 25].
Within studies, serotype-specific GMCs differed widely
between serotypes (see Fig. 2 Generally, GMCs tended
to be higher for serotype 14 compared to other sero-
types. Differences in serotype-specific GMCs were also
obvious between the different studies. For example,
GMCs measured by Musher et al. [12] were generally
higher than GMCs measured in the studies of Dransfield
et al. [23], Ohshima et al. [29], or Hammitt et al. [11]. In
all studies, GMCs tended to decline rapidly after an ini-
tial peak at 1 to 2 months after both primary vaccination
and revaccination.
One to two months after (re-)vaccination, GMC ratios
(GMC after second dose divided by GMC after first
dose) were mostly below 1, indicating higher short-term
immunogenicity of the first PPSV23 dose as compared
to the second dose, although these results were statisti-
cally not significant (Fig. 3 and Additional file 1). At
later time points, GMC ratios for most serotypes were
not different from 1, indicating that the ensuing long-
term immune responses to primary vaccination and
revaccination did not differ. In four studies in which
PPSV-23 antibodies were investigated over a period of
two or more years [12, 23, 25, 28], GMC ratios for some
serotypes (serotype 6B and 23F) increased to >1 (Fig. 2).
In the studies of Musher et al., GMC ratios increased
to >1 in the majority of analyzed serotypes 5 to 10
years after vaccination [12, 28]. Although absolute
antibody levels decreased continually over time, they
remained higher than the pre-vaccination levels before
Fig. 1 Flow chart for the systematic literature search and study selection
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Table 1 Characteristics of included studies









Prospective cohort studies (n = 10)
Tobudic, 20122 [31] Austria Adult renal transplant recipients,
50.5 (±13) yrs
29 (longitudinal cohort) 1 year 1, 4, 5, 7F, 9V, 14, 18C,
19F, 23F (WHO-ELISA)
Oesterreichische Nationalbank
Dransfield, 20122 [23] USA Patients with COPD, 64 (±10) yrs 42/48 Mean 8.4 (±3.5) years 4, 6B, 9V, 14, 18C, 19F,
23F (WHO-ELISA; OPA)
National Heart, Lung, and Blood Institute
Hammitt, 2011 [11] USA Alaska native population, 55–74 years 123/121 (2nd dose) and
71 (3rd or 4th dose)
6–22 years 1, 4, 6B, 14, 19 F
(non- WHO-ELISA; OPA)
US Department of Health and Human
Services - National Vaccine Program
Office
Jackson, 1999 [13] USA Resident population, 50–74 years 901/513 5–13 (median 6) years 4, 14, 23F (non-WHO-
ELISA; OPA)
CDC and Lederle Laboratories
Jackson, 2013 [22] USA Resident population with stable




3.5–4 years 1, 3, 4, 5, 6A, 6B, 7F, 9V,
14, 18C, 19A, 19F, 23F
(OPA)
Wyeth Vaccine Research/Pfizer
Manoff, 20104 [25] USA Resident population, 65–88 years 60/60 3–5 years 4, 14, 23F (Merck-ELISA;
OPA)
Funded in part by Merck & Co
and the CDC
Musher, 2010 [12] USA Resident population ≥ 50 year 437/5445 3–5 years 3, 4, 6B, 8, 9V, 12F, 14,
23F (Merck-ELISA)
Merck & Co
Musher, 20116 [28] USA Resident population 60–93 years 67 (2nd dose)/67
(3rd dose)
10 years 3, 4, 6B, 8, 9V, 12F, 14,
23F (Merck-ELISA)
Merck & Co
Ohshima, 2014 [29] Japan Paitents with COPD, 65–80+ yrs 40 (longitudinal cohort) 8–9 years 6B, 14, 19F, 23F
(WHO-ELISA; OPA)
Ministry of Health, Labour, and Welfare
of Japan
Törling, 2003 [24] Sweden Patients with history of CAP,
50–88 years




Retrospective database studies (n = 3)
Jackson, 2006 [27] USA Resident population, 50–80+ yrs 279,504/36,888
(2nd dose) and 603
(3rd dose)
1–9+ years (mean after
2nd dose 7 (±3) years)
Safety outcomes only Not reported
Shih, 2002 [30] USA Resident population, 65–80+ yrs 96,327/23,663 6 months-9 years (43%
> 5 years)
Safety outcomes only Centers for Medicare & Medicaid
Services
Walker, 2005 [32] USA Alaska native population, 72% ≥ 60
year
144/35 (2nd dose)
and 179 (≥3rd dose)
45% ≥ 6 years,
55% < 6 years
Safety outcomes only Funded in part by Association of
Schools of Public Health
Cross-sectional study (n = 1; telephone interview)
D’Heilly, 2002 [26] USA Elderly resident population, mean 71
year
455/107 not reported Safety outcomes only Not reported
COPD chronic obstructive pulmonary disease, ELISA enzyme linked immunosorbent assay, WHO World Health Organization, OPA Functional antibody activity assay, CDC centers for disease control and prevention, CAP
community acquired pneumonia
1In some studies, some analyses (e.g. safety) were conducted in smaller subpopulation; 2Published as randomized controlled trial but treated as cohort study here; 3 Not all patients were considered for all endpoints;















Table 2 Characteristics of included studies (continued)
Author, year [Ref] Number of study groups Safety assessment Statistically significant differences in baseline
characteristics and safety outcomes between primary
and revaccination dose of PPSV-23
Prospective cohort studies (n = 10)
Tobudic, 20121 [31] 1 (longitudinal cohort) 7 day diary (after
revaccination dose)
Population characteristics: Participants 1 year older at
2nd dose
Safety: no comparison group
Dransfield, 20121 [23] 2 (1st vs. 2nd dose) not assessed Population characteristics: 2nd dose recipients older,
more often white, more severe COPD disease
Safety: −
Hammitt, 2011 [11] 3 (1st vs. 2nd or 3rd dose) 4 day diary and
interview on day 30
Population characteristics: 2nd/3rd dose recipients older,
more likely Alaska Natives/American Indians, more
often with underlying comorbidities compared to 1st
dose recipients
Safety: local AEs and systemic AEs more frequent in
revaccination group
Jackson, 1999 [13] 2 (1st vs. 2nd dose) 13 day diary and
telephone interview
Population characteristics: 2nd dose recipients more
often females and less often with underlying
comorbidities
Safety: local AEs more frequent in revaccination group
at days 0–2, no differences after 6 days. No differences
regarding systemic AEs. Multivariate analysis:
revaccination independently associated with risk of
sizable local reaction
Jackson, 2013 [22] 1 (longitudinal cohort) 13 day diary Population characteristics: Participants 3.4–5 years older
at 2nd dose
Safety: local AEs and systemic AEs more frequent in
revaccination group
Manoff, 20102 [25] 2 (1st vs. 2nd dose) not assessed Population characteristics: 2nd dose recipients more
likely ever smoked
Safety: −
Musher, 20103 [12] 2 (1st vs. 2nd dose) 14 day diary Population characteristics: 2nd dose recipients more
often with underlying comorbidities
Safety: local AEs and systemic AEs more frequent in
revaccination group
Musher, 20113,4 [28] 2 longitudinal cohorts
(1st vs. 2nd; 2nd vs. 3rd)
14 day diary Population characteristics: Participants of both
longitudinal cohorts were ten years older at 2nd/3rd
dose
Safety5: local AEs and systemic AEs more frequent in
revaccination group
Ohshima, 2014 [29] 1 (longitudinal cohort) 14 day diary Population characteristics: Participants were 7.6 years
older at 2nd dose
Safety: local AEs and systemic AEs more frequent in
revaccination group
Törling, 2003 [24] 1 (longitudinal cohort) not assessed Population characteristics: Participants were 5.3 years
older at 2nd dose and 11% had a new episode of
pneumonia
Safety: no comparison group
Retrospective database studies (n = 3)
Jackson, 2006 [27] 3 (1st vs. 2nd vs. 3rd dose) ICD-9-Codes Population characteristics: 3rd dose recipients were
older and had more likely underlying comorbidities
Safety: Presumptive medically attended injection site
reaction more frequent in 2nd dose recipients than in
1st dose recipients. No statistically significant differences
between 1st dose and 3rd dose recipients
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Table 2 Characteristics of included studies (continued) (Continued)
Shih, 2002 [30] 2 (1st vs. ≥ 2nd dose) ICD-9-Codes Population characteristics: 2nd dose recipients were
older, more often white and had higher hospitalizations
rates and a higher comorbidity (Charlson) Index
Safety: Mulitivariate analysis: Revaccination
independently associated with emergency room visits
and office visits if PPSV-23 was administered within
5 years. No association after >5 years.
Walker, 2005 [32] 2 (1st or 2nd vs. ≥ 3rd dose) ICD-9-Codes and
medical records
Population characteristics: ≥ 3rd dose recipients were
older and had more likely underlying lung diseases
Safety: No differences in risk of medically attended AEs
in the different groups
Cross-sectional study (n = 1; telephone interview)
D’Heilly, 2002 [26] 2 (1st vs. ≥ 2nd dose) Interview 8 months
(on average) after
vaccination
Population characteristics: not reported
Safety: Multivariate analysis: Revaccination
independently associated with redness or swelling at
injection site during week after vaccination
1Published as randomized controlled trial but treated as cohort study here; 2Substudy of Musher et al. [12]; 3Musher [28] is extension study of Musher et al. [12]; 4
two longitudinal cohorts: cohort one received 1st dose in 1997 and 2nd in 2007; cohort two received 2nd dose in 1997 and 3rd in 2007; 52nd vs. 3rd dose (1st vs.
2nd dose reported in Musher [12])
Fig. 2 Geometric mean concentrations (GMC) with 95% confidence intervals of the most commonly analyzed serotypes (4, 6B, 14, 23F)
Remschmidt et al. BMC Infectious Diseases  (2016) 16:711 Page 7 of 12
primary vaccination or revaccination. Ratios could not
be calculated for three studies since either absolute
numbers or 95% CIs were not available [23–25].
OPA data were available for analysis from 4 of 5 studies
and revealed contradictory results. In the study of
Hammitt et al. [11], 2 of 5 serotypes showed greater
immune response one month after revaccination dose
than after the primary dose given 6–22 years earlier (see
Additional file 1). Jackson et al. [22] found that OPA
immune response after primary vaccination was signifi-
cantly higher in 9 of 14 analyzed serotypes compared to
revaccination 3–4 years later. Manoff et al. found for the
three investigated serotypes comparable OPA values one
month after primary and secondary vaccination [25].
Finally, in the study of Ohshima et al., no statistically sig-
nificant differences of OPA values were found in 4 ana-
lyzed serotypes [29]. One study did not provide data of a
primary PPSV-23 dose as compared to revaccination [23].
Taken together, these results suggest that revaccination
with PPSV-23 may induce a less pronounced rise of anti-
body levels than the primary vaccination in the first 2
months after vaccination, which, however, does not impair
long-term persistence of anti-polysaccharide antibodies.
Safety of primary vaccination and revaccination with
PPSV-23
Ten of 14 studies compared frequency and/or severity
of AEs after primary and revaccination doses with
PPSV-23 (see Table 1). In four studies, safety of ≥ 3
doses was assessed [11, 27, 28, 32]. Safety data were
collected through patient diaries [11–13, 22, 28, 29],
by analyzing ICD-9 codes and/or medical records of
vaccinated subjects [27, 30, 32] or by telephone inter-
view of vaccinees [26].
There was a wide range of reported safety endpoints
ranging from two [31] to seven [13] local AEs, such as
redness, swelling or limitation of arm movement, and
from five [11, 28] to twelve [22] systemic AEs, such as
arthralgia, fatigue, fever, headache, nausea, myalgia or
rash. Additionally, local and/or systemic AEs were graded
as mild, moderate or severe in the majority of the studies.
Fig. 3 Ratios (2nd dose/1st dose) of geometric mean concentrations (GMC) with 95% confidence intervals of the most commonly analyzed serotypes
(4, 6B, 14, 23F)
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Frequency of local and systemic AEs differed widely
between the six studies in which patient diaries were
used [11–13, 22, 28, 29]. For example, fever ranged from
0 to 9% [22, 28] after the primary dose and from 2 to
10% [13, 22] after revaccination dose, any headache
from 2 to 61% [22, 29] in primary vaccinated and
from 13 to 57% [13, 22] in revaccinated individuals.
Limitation of arm movement ranged from 4 to 31%
[11, 22] after primary and from 13 to 47% [11, 22]
after revaccination.
Of four studies in which occurrence of AEs in correl-
ation with (higher) pre-vaccination antibody levels was
assessed, three studies found an association [11–13] and
one study did not [24]. Regarding the time span since
previous vaccination, two [28, 30] of 5 studies found that
a longer time period (>5 to 10 years) since primary vac-
cination reduced severity and/or frequency of AEs. The
remaining studies [13, 26, 27] did not find a statistically
significant association between time span since primary
vaccination and severity of AEs.
In studies that used ICD-9 codes to assess differences in
vaccine-related unplanned medical visits, differences were
smaller and ranged from 0.3 to 1.3% after primary and
from 0.7 to 1.9% after revaccination doses [27, 30, 32, 34].
Of four studies in which safety of a third dose was
analyzed, one study found more local and systemic AEs
among third-dose recipients than among second-dose re-
cipients [28], whereas another study found no differences
between second-dose and third- or fourth-dose recipients
[11]. In the remaining two studies, no differences in
medically attended AEs were identified after a third dose
compared to a first or second dose [27, 32].
Four studies provided adjusted safety analyses
[13, 26, 27, 30]. Jackson et al. found that revaccination
with PPSV-23 was independently associated with the risk
of a sizable local reaction [13]. In this study, the majority
of local adverse events disappeared within 6 days of vac-
cination. Shih et al. identified revaccination with PPSV-23
as a risk factor for emergency department visits or medical
office visits [30]. In the Vaccine Safety Datalink population
in the U.S., elderly with a second PPSV-23 dose had a
higher risk of a presumptive medically attended injection
site reaction than those who received a primary or a third
dose [27]. D’Heilly et al. found that revaccination was
independently associated with redness or swelling at the
injection site [26].
Overall, local AEs and systemic AEs after revaccin-
ation were reported more frequently in studies in which
patient diaries were used (Table 1). Two of four studies
found that unplanned medical visits were more frequent
after a revaccination dose [27, 30]. None of the studies
reported serious adverse events during the observation
periods after primary vaccination or revaccination,
respectively.
Discussion
Comparative data on the effectiveness of primary vs. re-
vaccination with PPSV-23 are still lacking. Since we did
not identify studies with clinical endpoints, evidence had
to be derived from immunogenicity studies only. These
studies indicated that antibody responses are reduced
during the first months after revaccination as compared
to primary vaccination with PPSV-23. However, differ-
ences were observed only for some serotypes and were
restricted to early time points (i.e. one or two months
after revaccination). Thereafter immunogenicity of
primary vaccination and revaccination was comparable.
After a period of more than two years antibody levels
against some serotypes were even higher after revaccin-
ation than after primary vaccination. Regarding safety,
our systematic review indicates that revaccination with
PPSV-23 is associated with a higher frequency of local
and systemic, self-limiting adverse events, but not with
severe sequelae.
Measuring the efficacy/effectiveness against clinical
outcomes has been advocated as the best way to assess
the protective effect of immunizations [35, 36]. However,
in the absence of such data, evidence has to be derived
from immunogenicity studies that evaluate antibody re-
sponses after immunization. For PCV, a working group
of the World Health Organization has defined in 2005 a
mean concentration of ≥0.35 μg/ml of serotype-specific
anti-polysaccharide IgG measured with ELISA one
month after immunization as a “correlate of protection”
against IPD in children [37]. However, it is unclear (i)
how well this threshold correlates with the efficacy of a
pneumococcal vaccine against clinical outcomes [36], (ii)
whether this threshold also applies to polysaccharide
vaccines and (iii) whether this threshold is also appropri-
ate for the adult or the elderly population. In addition,
since Andrews et al. showed that serotype-specific pro-
tection varies widely [38], serotype-specific thresholds
might be necessary. On the basis of the proven pro-
tective efficacy of a primary vaccination with PPSV-23
[39, 40], we believe that demonstration of comparable
immunogenicity more than 2 months after primary or
revaccination indicates that protective efficacy should
also be comparable and that an exact threshold is not
essential.
In addition to serotype-specific IgG, measurement of
functional antibodies as assessed by OPA is considered
as a valid surrogate parameter for vaccine protection
from pneumonia or bacteremia [23, 41, 42]. We identi-
fied 5 studies which assessed functional antibody activity
and 4 of those provided enough data to calculate OPA
ratios. According to these ratios, no uniform pattern was
observed. Although Jackson et al. demonstrated that
OPA immune responses one month after revaccination
were lower than responses after primary vaccination
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[22], such a pattern was not reported by the other studies.
In fact, Hammitt et al. found OPA immune responses to
be even higher one month after revaccination in 2 of 5 se-
rotypes [11]. Whether these inconsistencies result from
differences in the study population or laboratory methods,
could not be clarified with the available data.
It remains unclear why the rise in antibody levels after
revaccination with pneumococcal polysaccharide vaccine is
lower than after primary vaccination and if this might
affect clinical effectiveness [10]. Several mechanisms have
been discussed. For example, large amounts of polysaccha-
rides might deplete memory B cells and B1b cells [43, 44],
although this was not seen in other studies [45, 46]. Alter-
natively, other immune cells such as dendritic cells [47] or
T lymphocytes with suppressor activity [48–50] might re-
duce immunological response to polysaccharides. Given
these uncertainties, studies measuring clinical endpoints
after revaccination with PPSV-23 are urgently needed.
Data on the safety of a revaccination vs. primary
PPSV-23 dose were more consistent and indicate that
revaccination with PPSV-23 is associated with a higher
number of non-severe AEs as compared to the primary
dose. However, since in the majority of studies partici-
pants of the revaccination groups were older and/or had
more comorbidities than the comparison group, inter-
pretation of the unadjusted rates of AEs has to be taken
with caution. The fact that revaccination increases the risk
of AEs is consistent with Arthus-type hypersensitivity
reactions in which antigen-antibody complexes cause local
symptoms after (re-)vaccination [13, 51]. Since this
phenomenon requires residual antibodies, it seems
plausible that a longer time span since the previous
vaccination - accompanied by declining antibody levels -
will reduce these reactions. This has been shown in 2 of 5
studies that investigated a time-depended frequency or se-
verity of AEs and in 3 of 4 studies in which a correlation
between pre-vaccination GMCs and (local) AEs was
found. Therefore, revaccination after a longer time period
(e.g. > 5 years) seems appropriate.
Strengths and weaknesses of this study
This study has several strengths. It is based on a com-
prehensive systematic review of the currently available
literature, comprising immunogenicity as well as safety
data. By calculating the ratios of GMTs, we provide a
measure of relative immunogenicity of revaccination,
which is independent of differences of laboratory assays
used in different studies. The usefulness of this approach
was limited by differences in the choice and numbers of
serotypes analyzed in different studies.
Interpretation of the immunogenicity data was compli-
cated by differences in the composition of study popula-
tions (e.g., different age-groups, patients with COPD vs.
resident population vs. renal transplant recipients) and
differences regarding the follow-up period and time points
at which blood sampling was performed. In addition, risk
of bias was high in the majority of studies, limiting the
internal validity of the results. Since no study reported
adjusted immunological data, it remains unclear to what
extend confounders such as comorbidities might have
influenced the results. Furthermore, in some studies it
remained unclear how selection of participants into the
cohorts was performed. For these and further reasons
related to heterogeneity of the study designs, it was not
possible to calculate meta-analytical estimates.
Conclusion
In conclusion, comparative data on the effectiveness of pri-
mary vs. revaccination with PPSV-23 are still missing,
mainly due to the lack of randomized controlled trials
using clinical endpoints. The available evidence from ob-
servational studies indicates that revaccination with PPSV-
23 is likely to induce long-term antibody levels that are
comparable to those after primary vaccination. However,
due to differences in study design, study populations,
different intervals between doses and high or unclear risk
of bias in the included studies, these results have to be
taken with caution and it remains unclear how immuno-
genicity results translate into clinical protection. Since pri-
mary vaccination with PPSV-23 has been shown to protect
from pneumococcal disease, it seems likely that – based on
similar antibody levels - also revaccination may confer. In
view of the waning immunity and increasing risk of severe
pneumococcal disease with age, the benefits of revaccin-
ation with PPSV-23 probably outweigh the increased risk
of non-severe local and systemic AE. Revaccination could
therefore be considered in the elderly after informing about
benefits and possible harms of revaccination. In order to
obtain strong evidence for the effectiveness of PPSV-23 in
the elderly, RCTs or carefully designed observational stud-
ies using clinical relevant endpoints are urgently needed.
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